Some indications like NSCLC and cancer of unknown primary (CUP) have a high prevalence of homozygous SMARCA4 mutations with >40% representing truncating alterations suggesting clear loss-of-function (Fig. 1c). Here, SMARCA4 is linked to non-small cell lung carcinoma.